Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply - CNBC

What the report says

CNBC reported that President Donald Trump is proposing tariffs on imported generic medicines that would begin after a two-year grace period, then rise to 100% for one year and 200% afterward. The administration’s stated aim is to encourage more pharmaceutical production in the United States, but the plan’s details remain unresolved, including whether duties would cover only finished imported medicines or also products made domestically with imported active ingredients.

The proposal could have a sharper effect on generic drugmakers than on branded pharmaceutical companies because generics typically compete on price after patent protections expire and often operate with narrow margins. CNBC noted that generics account for about 90% of U.S. prescriptions but a much smaller share of overall drug spending because prices are comparatively low. Industry figures and analysts cited by CNBC said manufacturers may have to absorb higher costs, raise prices where possible, shift production, or exit products that become unprofitable.

John Murphy III, head of the Association for Accessible Medicines, told CNBC the industry supports policies that stabilize access to affordable medicines, while arguing that purchasing and reimbursement problems also discourage U.S. production. Namit Joshi of India’s Pharmexcil said building a domestic generic manufacturing base can take at least four to five years, longer than the proposed grace period.

Analysts cited by CNBC said companies with existing U.S. manufacturing, including Amphastar, ANI Pharmaceuticals, Hikma and Fresenius Kabi, may be better positioned. Firms such as Teva, Viatris and Apotex may face more exposure because more of their U.S.-sold products are made abroad. The impact on medicine prices and supply will depend heavily on the final rules and implementation.